COMPANY

GV20 Therapeutics

Profile checked Oct 10, 2026

Keywords: Endometrial Carcinoma Squamous Head and Neck Carcinoma pMMR/MSS Adenocarcinoma of the Colon or Rectum Non-Small Cell Lung Cancer Uterine Cervical Neoplasms Triple Negative Breast Neoplasms Prostatic Neoplasms Squamous Cell Carcinoma of Head and Neck Esophageal Squamous Cell Carcinoma Cholangiocarcinoma Gallbladder Neoplasms Colorectal Neoplasms Pancreatic Ductal Adenocarcinoma Non-Small-Cell Lung Carcinoma Small Cell Lung Carcinoma Solid Tumor Cancer Melanoma HCC - Hepatocellular Carcinoma Small Cell Lung Cancer Cutaneous Melanoma GV20-0251

3Trials (company is sponsor)

Timeline

Jun 2, 2026 Trial start II: A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. source ↗
Jul 11, 2025 Trial start Phase 1/Phase 2: Study of GV20-0251 in Participants With Solid Tumor Malignancies source ↗
Mar 23, 2023 Trial start Phase 1/Phase 2: A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies source ↗

Upcoming milestones

Dec 15, 2026 (ESTIMATED) · Phase 1/Phase 2 · A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies · NCT05669430
Jul 16, 2027 (ESTIMATED) · Phase 1/Phase 2 · Study of GV20-0251 in Participants With Solid Tumor Malignancies · NCT07070518
Jun 15, 2028 (ESTIMATED) · II · A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. · NCT07623642

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07623642	A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.	II	Not yet recruiting	Jun 2, 2026	Jun 15, 2028 (estimated)
NCT07070518	Study of GV20-0251 in Participants With Solid Tumor Malignancies	Phase 1/Phase 2	Recruiting	Jul 11, 2025	Jul 16, 2027 (estimated)
NCT05669430	A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies	Phase 1/Phase 2	Recruiting	Mar 23, 2023	Dec 15, 2026 (estimated)